Jagsonpal Pharma buys hospital distributor for ₹20.8 cr
The cash deal adds ₹53 cr in revenue and a hospital channel, funded entirely from internal accruals.
What's new
- Jagsonpal to acquire 85% of hospital distributor Aequitas for ₹20.8 cr cash
- Aequitas FY26 revenue of ₹53.31 cr adds ~18.6% to Jagsonpal's top line
- Deal funded from internal accruals; no regulatory approvals needed; close by July 15, 2026
Why this matters
The acquisition diversifies Jagsonpal from retail/OTC into institutional hospital distribution, a channel with higher volume and recurring revenue. For a debt-free company with 23% ROE, this is a capital-efficient bolt-on that immediately boosts revenue and opens access to hospital chains.
What we're watching
- Integration of Aequitas and margin impact on Jagsonpal's profitability
- Whether Jagsonpal pursues further hospital-channel acquisitions
- Retention of Aequitas founders and continuity of operations
The full read
A clean deal. Jagsonpal is paying ₹20.8 crore in cash, with no debt, for 85% of hospital distributor Aequitas Healthcare—a business that generated ₹53.31 crore in FY26 revenue, roughly 18.6% of Jagsonpal's own. Founders retain 15% and remain. No regulatory approvals needed, no related-party complications. For a micro-cap trading at 34x earnings with 23% ROE, this is a capital-efficient bolt-on that diversifies revenue into institutional channels and instantly lifts the top line. The next test: integration and whether distribution margins hold up against core pharma margins.
Questions answered
- Why is this deal significant for Jagsonpal?
- It enters the hospital distribution segment, a new channel that can scale branded products. Aequitas' ₹53 cr revenue is about 18.6% of Jagsonpal's consolidated revenue, providing immediate top-line growth.
- How is the acquisition funded?
- Entirely from internal accruals. Jagsonpal had zero debt and strong cash generation, making this a debt-free acquisition.
- What are the key terms?
- 85% stake for ₹20.8 crore cash. The existing directors retain 15% and continue to run the business. It is not a related-party deal and requires no regulatory approvals.
- When will the transaction close?
- Expected to close by July 15, 2026.
- What is Aequitas Healthcare's business?
- A hospital-focused pharmaceutical distributor founded in 2017, serving leading hospital chains across India.
- How will this affect Jagsonpal's financials?
- Immediate revenue boost of about 18.6%. Profitability impact depends on distribution margins, but the cash funding avoids interest costs.